Global Health Limited (MEDANTA) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹1,429.3 (+2.28% day change)
Key ratios
- P/E ratio
- 69.01
- P/B ratio
- 6.52
- ROE (%)
- 14.05
- ROCE (%)
- 13.2
- Debt/Equity
- 0.3
- Dividend yield (%)
- 0.05
- Market cap (₹ Cr)
- 38,430.67
Forensic checks
Piotroski F-Score: 4/9 · Altman Z-Score: 8.92 · Beneish M-Score: -2.16
InvestSights quality score
66.7/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Noida hospital launch bed capacity: guided 300beds, delivered 300beds (Q2 FY26) — met guidance
- Noida bed capacity scale-up: guided 550beds, delivered 300beds (Q2 FY26) — missed guidance
Latest earnings call (Q1 FY27)
AI summary: The single most important signal from this concall is the dramatic acceleration in Medanta Noida's financial trajectory — EBITDA losses narrowed from ₹23.6 crore in Q4 FY26 to just ₹4.9 crore in Q1 FY27, while revenues nearly doubled quarter-on-quarter to ₹85.5 crore, prompting management to guide that EBITDA breakeven will arrive "earlier than our previous expectations."…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.